The Future of Anti-Infectives ESTABLISH 2 Top Line Data Release March 25, 2013 Exhibit 99.2 |
2 Forward Looking Statements Statements contained in this data release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward- looking statements include: the accuracy of Trius’ estimates regarding expenses, future revenues and capital requirements; the success and timing of Trius’ preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Trius’ plans to develop and commercialize its product candidates; Trius’ ability to obtain additional financing; Trius’ ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Trius’ most recently filed SEC documents, including its Form 10-K, Forms 10-Q and other documents filed with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in such filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trius undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. |
3 ESTABLISH 2 (IV/PO) Phase 3 Trial Design 2 o EMA 1 o EMA Tedizolid Linezolid 1x 200mg 2x 600mg n=666 1 o FDA 2 o FDA Placebo Post-Treatment Evaluations END-POINTS FOR GLOBAL REGISTRATION Safety Analysis Non-inferiority trial design vs. Linezolid |
4 ESTABLISH 2 Primary & Secondary Endpoints Primary Endpoint: • 20% or greater reduction in lesion area at 48-72 hours after first dose of drug Secondary Endpoints: • Programmatic clinical response at end of therapy (EOT) • Investigator’s assessment of clinical response at post treatment evaluation (PTE) |
5 ESTABLISH 2 Demographics and Baseline Characteristics Tedizolid, % n = 332 Linezolid, % n = 334 Male, % 67.8 64.1 Age, mean 45.6 45.6 Geographic Region, % North America (US) 47.0 47.3 Ex-U.S. 53.0 52.7 Clinical Syndrome, % Cellulitis/erysipelas 50.0 50.3 Major abscess 20.5 20.4 Wound infection 29.5 29.3 MRSA (MITT), % 27.2 26.9 MSSA (MITT), % 52.8 53.0 Lymphadenopathy, % 70.8 70.4 WBC < 4,000 or > 10,000, % 53.0 45.2 Immature neutrophils, % 16.2 12.2 Fever, % 31.0 29.0 |
6 ESTABLISH 2 Efficacy ITT Analysis Set Endpoint Tedizolid 6 days treatment, % n = 332 Linezolid 10 days treatment, % n = 334 Treatment Difference (95% CI), % Primary Endpoint >20% decrease from baseline in lesion area at 48-72 hours 85.2 82.6 2.6 (-3.0 to 8.2) Key Secondary Endpoints Sustained clinical response at end of therapy 87.0 88.0 -1.0 (-6.1 to 4.1) Investigators assessment of clinical response at 7-14 days after end of therapy 88.0 87.7 0.3 (-4.8 to 5.3) Sensitivity analysis (2010 FDA Guidance) Cessation of lesion spread and absence of fever at 48-72 hours 85.8 81.4 4.4 (-1.2 to 10.1) |
7 ESTABLISH 2 Efficacy by Infection Type ITT Analysis Set Tedizolid 6 days treatment, % n = 332 Linezolid 10 days treatment, % n = 334 Treatment Difference (95% CI), % Cellulitis/erysipelas 80.7 n = 166 80.4 n = 168 0.37 (-8.2 to 8.9) Major cutaneous abscess 86.8 n = 68 89.7 n = 68 -2.9 (-14.5 to 8.4) Wound infection 91.8 n = 98 81.6 n = 98 10.2 (0.71 to 20.1) |
8 ESTABLISH 2 Safety: Tedizolid was Safe and Well Tolerated with a Favorable AE Profile vs. Linezolid Safety Analysis Set Tedizolid 6 days treatment, % Linezolid 10 days treatment, % Any Treatment Emergent Adverse Event (TEAE) 45.3 43.7 Any Drug Related TEAE 20.5 24.8 Gastrointestinal Disorders 16.0 20.5 No Safety Signals |
9 ESTABLISH 2 Incidence of TEAEs >2% System Organ Class Tedizolid, (%) n = 331 Linezolid, (%) n =327 Gastrointestinal disorders 53 (16.0) 67 (20.5) General disorders and administration site conditions 23 (6.9) 24 (7.3) Infections and infestations 40 (12.1) 40 (12.2) Metabolism and nutrition disorders 9 (2.7) 7 (2.1) Musculoskeletal and connective tissue disorders 9 (2.7) 9 (2.8) Nervous system disorders 29 (8.8) 36 (11.0) Psychiatric disorders 10 (3.0) 4 (1.2) Respiratory, thoracic and mediastinal disorders 6 (1.8) 13 (4.0) Skin and subcutaneous tissue disorders 21 (6.3) 24 (7.3) Vascular disorders 7 (2.1) 4 (1.2) |
10 ESTABLISH 2 Post-Baseline Substantially Abnormal Hematology Values Tedizolid, (%) n = 331 Linezolid, (%) n =327 Hemoglobin 292 287 Below LLN 147 (50.3) 148 (51.6) Substantially abnormal 4 (1.4) 2 (0.7) White blood cells 272 258 Below LLN 16 (5.9) 20 (7.8) Substantially abnormal 3 (1.1) 5 (1.9) Platelets 275 269 Below LLN 37 (13.5) 35 (13.0) Substantially abnormal 9 (3.3) 5 (1.9) |
11 Differences Between ESTABLISH 1 and 2 ESTABLISH 2 ESTABLISH 1 Dosing IV to oral (minimum 1 st day’s dosing IV) Oral Demographics US 47%, x-US 53% US 80%, x-US 20% MRSA, % 27.1 42.6 Primary Endpoint* > 20% reduction in lesion area @ 48 to 72 hours Cessation of lesion spread, absence of fever @ 48 to 72 hours *ESTABLISH 2 SPA amended under agreement with FDA to reflect expected new primary endpoint. Both endpoints prospectively captured as sensitivity analyses in respective studies. Integrated summary of efficacy will reflect the ESTABLISH 2 primary endpoint under the amended SPAs |
12 ESTABLISH Program Comparison Endpoint Study Tedizolid 6 days treatment, % Linezolid 10 days treatment, % Treatment Difference (95% CI), % >20% decrease from baseline in lesion area at 48-72 hours ESTABLISH 2 ESTABLISH 1 85.2 78.0 82.6 76.1 2.6 (-3.0 to 8.2) 1.9 (-4.5 to 8.3) Sustained clinical response at end of therapy ESTABLISH 2 ESTABLISH 1 87.0 87.0 88.0 87.8 -1.0 (-6.1 to 4.1) -0.8 (-5.8 to 4.4) Investigators assessment of clinical response at 7- 14 days after end of therapy ESTABLISH 2 ESTABLISH 1 88.0 85.5 87.7 86.0 0.3 (-4.8 to 5.3) -0.5 (-5.8 to 4.9) Cessation of lesion spread and absence of fever at 48-72 hours ESTABLISH 2 ESTABLISH 1 85.8 79.5 81.4 79.4 4.4 (-1.2 to 10.1) 0.1 (-6.1 to 6.2) |
13 ESTABLISH Program Safety Comparison Safety Analysis Set Study Tedizolid % Linezolid % Any Treatment Emergent Adverse Event (TEAE) ESTABLISH 2 45.3 43.7 ESTABLISH 1 40.8 43.3 Any Drug Related TEAE ESTABLISH 2 20.5 24.8 ESTABLISH 1 24.2 31.0 Gastrointestinal Disorders ESTABLISH 2 16.0 20.5 ESTABLISH 1 16.3 25.4 |
14 Summary • All primary and secondary efficacy endpoints were met for FDA and EMA • Safety profile indicated that tedizolid was safe and well tolerated • Results are consistent with those from ESTABLISH 1 and support filings for global regulatory approval • Combined results of all clinical studies support tedizolid differentiation: – Safe, well tolerated, fast acting drug for resistant gram positive infections – Convenient once daily IV or oral administration over short course of therapy – Fewer drug-drug interactions – Active against key linezolid resistant strains |
15 *Efficacy performance ratings among those aware of brand Tedizolid ATU Study, Wave 1 – USA Report, conducted by CMI on behalf of Trius, November 2012, N=505 Strong Response to Tedizolid Efficacy, Dosing and Administration * Tedizolid, 65% Tedizolid, 52% Zyvox, 62% Zyvox, 42% Cubicin, 54% Cubicin, 37% Vancomycin, 25% Vancomycin, 27% Tedizolid, 45% Tedizolid, 42% Zyvox, 45% Zyvox, 38% Cubicin, 42% Cubicin, 37% Vancomycin, 30% Vancomycin, 30% Offers simple dosing and administration Has a lower potential for resistance development Has superior efficacy vs. other products Is effective for all patient types |
16 Strong Response to Tedizolid Safety & Tolerability Has a low frequency of DDI (drug-drug interaction) Does not cause renal and hepatic impairment Has a low frequency of safety/adverse events *Efficacy performance ratings among those aware of brand Tedizolid ATU Study, Wave 1 – USA Report, conducted by CMI on behalf of Trius, November 2012, N=505 Tedizolid, 48% Tedizolid, 53% Tedizolid, 59% Zyvox, 27% Zyvox, 45% Zyvox, 31% Cubicin, 48% Cubicin, 42% Cubicin, 44% Vancomycin, 39% Vanco ., 14% Vancomycin, 25% |
17 Tedizolid ATU Study, Wave 1 – USA Report, conducted by CMI on behalf of Trius, November 2012, N=505 Base: Total respondents Q8.1 How interesting is tedizolid to you for suspected or confirmed MRSA ABSSSI patients overall? Use a 1 to 10 scale where “1” means “Not at all Interesting” and “10” means “Very Interesting,” to indicate your level of interest. Interest in Tedizolid, by Specialty (0 = Not Interested, 10 = Very Interested) Physician Interest in Tedizolid Strong Across Specialties Total (N = 505) Critical Care, Pulmonologist (n = 120) Internist (n = 137) General Surgeon (n = 86) Hospitalist (n = 175) Infectious Disease Specialist (n = 101) Infusion Clinic Specialist (n = 75) 80% 69% 74% 72% 76% 92% 83% 19% 31% 25% 27% 23% 7% 17% High Interest (8-10) Neutral (4-7) Low Interest (1-3) |
18 Upcoming Milestones • Late breaker presentations at ECCMID conference (submitted for April) • Detailed data presentations at ICAAC conference (September) • Advance EU partnership discussions • NDA Filing (H2 2013) • Implement pre-commercial activities for potential U.S. launch (H2 2013) • Initiation of Phase 3 ventilated nosocomial pneumonia study (H2 2013) • EMA Filing (H1 2014) • Potential PDUFA date for ABSSSI (mid 2014) |